Rafael Ríos-Tamayo1, María José Sánchez2, José Manuel Puerta3, Juan Sáinz4, Daysi-Yoe-Ling Chang5, Teresa Rodríguez6, Pilar López3, José María de Pablos3, Pilar Navarro3, José Luís García de Veas6, Antonio Romero3, Pilar Garrido3, Lucía Moratalla3, Carolina Alarcón-Payer7, Elisa López-Fernández3, Pedro Antonio González3, José Juan Jiménez-Moleón8, Miguel Ángel Calleja-Hernández9, Manuel Jurado4. 1. Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves, Granada, Spain; Department of Hematology, University Hospital Virgen de las Nieves, Granada, Spain; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. Electronic address: rriost33@gmail.com. 2. Granada Cancer Registry, Andalusian School of Public Health, Granada, Spain; CIBER Epidemiology and Public Health, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 3. Department of Hematology, University Hospital Virgen de las Nieves, Granada, Spain. 4. Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves, Granada, Spain; Department of Hematology, University Hospital Virgen de las Nieves, Granada, Spain; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 5. Granada Cancer Registry, Andalusian School of Public Health, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 6. Department of Inmunology, University Hospital Virgen de las Nieves, Granada, Spain. 7. Pharmacy Department, University Hospital Virgen de las Nieves, Granada, Spain. 8. CIBER Epidemiology and Public Health, Granada, Spain; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 9. Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain; Pharmacy Department, University Hospital Virgen de las Nieves, Granada, Spain.
Abstract
BACKGROUND: Despite the progress made in recent years, multiple myeloma is still considered an incurable disease. Most survival data come from clinical trials. Little is known about the outcome in unselected real-life patients. METHODS: Overall survival was analyzed in a cohort of newly diagnosed symptomatic multiple myeloma patients, over the last three decades, in a single institution population-based study. RESULTS: 582 consecutive myeloma patients were included in the study. Survival increased over time in patients younger than 65 years but did not reach statistical significance in patients with 65 years or older. The prognostic factors associated with overall survival were the International Staging System, the serum lactate dehydrogenase level, the renal impairment, the realization of autologous stem cell transplantation, and the presence of concomitant amyloidosis. Overall survival shows a steady improvement over time. INTERPRETATION: The survival of myeloma is improving progressively in real-life patients, particularly after the widespread use of the novel agents. A comprehensive assessment of comorbidity can help to explain the huge heterogeneity of myeloma outcome. The optimization of current therapeutic resources as well as the incorporation of new drugs will allow further improvement of survival in the coming years.
BACKGROUND: Despite the progress made in recent years, multiple myeloma is still considered an incurable disease. Most survival data come from clinical trials. Little is known about the outcome in unselected real-life patients. METHODS: Overall survival was analyzed in a cohort of newly diagnosed symptomatic multiple myelomapatients, over the last three decades, in a single institution population-based study. RESULTS: 582 consecutive myelomapatients were included in the study. Survival increased over time in patients younger than 65 years but did not reach statistical significance in patients with 65 years or older. The prognostic factors associated with overall survival were the International Staging System, the serum lactate dehydrogenase level, the renal impairment, the realization of autologous stem cell transplantation, and the presence of concomitant amyloidosis. Overall survival shows a steady improvement over time. INTERPRETATION: The survival of myeloma is improving progressively in real-life patients, particularly after the widespread use of the novel agents. A comprehensive assessment of comorbidity can help to explain the huge heterogeneity of myeloma outcome. The optimization of current therapeutic resources as well as the incorporation of new drugs will allow further improvement of survival in the coming years.
Authors: D-Y-L Chang-Chan; R Ríos-Tamayo; M Rodríguez Barranco; D Redondo-Sánchez; Y González; R Marcos-Gragera; M J Sánchez Journal: Clin Transl Oncol Date: 2021-01-12 Impact factor: 3.405
Authors: Emily B Martin; Angela Williams; Craig Wooliver; R Eric Heidel; Sarah Adams; John Dunlap; Marina Ramirez-Alvarado; Luis M Blancas-Mejia; Ronald H Lands; Stephen J Kennel; Jonathan S Wall Journal: PLoS One Date: 2017-03-28 Impact factor: 3.240
Authors: Rafael Ríos-Tamayo; Agustín Martín-García; Carolina Alarcón-Payer; Dolores Sánchez-Rodríguez; Ana María Del Valle Díaz de la Guardia; Carlos Gustavo García Collado; Alberto Jiménez Morales; Manuel Jurado Chacón; José Cabeza Barrera Journal: Drug Des Devel Ther Date: 2017-08-22 Impact factor: 4.162